You just read:

Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation

News provided by

Intarcia Therapeutics, Inc.

Apr 27, 2015, 09:55 ET